Introduction Increasing evidence points to the autoimmune process of rheumatoid arthritis (RA) originating at mucosal surfaces. Previous work from our group described a subset of B cells in the synovium and synovial fluid (SF) of RA patients distinguishable by their expression of Fc-like receptor 4 (FcRL4) and elevated expression of RANKL, indicating a unique pathogenic function. 1, 2 B cells expressing FcRL4 were originally described as a distinct memory B cell subset in human tonsils where they are localised in the epithelium. 3 We have recently shown in RA that they are enriched in clones recognising citrullinated autoantigens. 3 Recent in vitro work suggested that FcRL4 is a low affinity receptor for aggregated IgA. Introduction B-cells have a well-established role in the pathogenesis of rheumatoid arthritis (RA), illustrated by the successful treatment of RA with B-cell depletion therapy. 1 Sialic acid (SA) is a 9-carbon backbone sugar involved in many immune system functions including cell migration, adhesion and activation. 2 In RA, sialylation of the B-cell surface, including membrane bound IgM, has been found to differ from healthy control B-cells. These changes have been attributed to alterations in antibody glycosylation which lead to the highly inflammatory phenotype of disease-specific autoantibodies. 3 Recently it has been shown that surface glycosylation of regulatory T-cells is altered by activating stimuli -suggesting functional consequences for cell surface glycans. 4 Functional effects of surface glycans in B-cells in RA have not been well established.
Objectives The aim of this study is to investigate surface sialylation of B-cells from patients with RA at different stages of disease, and to examine functional consequences of B-cell surface sialylation. Methods Sialylation of peripheral blood mononuclear cells isolated from 7 patients with either 'pre-RA' or RA (3 patients with ACPA+ 'pre-RA', 1 patient with a diagnosis of new onset, £12 months symptom duration, and 3 patients with established disease) was analysed by flow cytometry using biotinylated Sambucus Nigra (SNA) Lectin, to bind to a2,6 SA, with PE-conjugated streptavidin. MESF beads were used to standardise the measurement of fluorescence intensity. B-cells were activated in culture with anti-CD40 and anti-IgM. Results Initial data suggests that B-cell surface sialylation may be higher in patients with pre-RA (MESF: 13765±170) or new onset RA (13094) than in patients with established RA (12431.3±339). Sialylation also tended to be higher on plasmablasts (1396±991) than on memory (13067±496) or naïve B-cells (13127±710). Upon in vitro activation with anti-CD40 and anti-IgM, sialylation tended to decrease in plasmablasts (20042±679 vs 16200.5±1261).
Conclusions Preliminary results suggest that B-cell surface sialylation may vary according to stage of disease and B-cell subset. Sialylation may also be related to B-cell activation. Further investigations will be carried out to better understand variations in surface sialic acid and examine the relationship between B-cell function and surface sialylation.
